» Articles » PMID: 24715162

Proatherogenic Adipocytokines Levels in Metabolic Syndrome

Overview
Date 2014 Apr 10
PMID 24715162
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Metabolic syndrome was defined by IDF (International Federation for Diabetes, 2007) by abdominal obesity plus at least two of the following: high triglycerides, low HDL-cholesterol, hypertension, high levels of glucose or type II diabetes diagnosed. Obesity is associated with a high cardiovascular risk, abdominal obesity being the most aggressive form, because it secretes cytokines and hormones in comparison to subcutaneous adipose tissue. Adipocytokines secreted by adipose tissue are mediators of atherosclerosis and endothelial damage.

Materials And Methods: We studied a total of 80 subjects aged between 40 and 60 years with metabolic syndrome, in which the following adipocytokines values were determined: hs-CRP (turbidimetric method), IL-6, TNF-alpha, leptin (ELISA method), in comparison to a control group.

Results: The values of these adipocytokines were significantly higher in the studied group compared with the control group and correlated with increased levels of glucose (patients with type II diabetes or increased tolerance test) and with hyper-triglyceridemia.

Conclusions: Patients with metabolic syndrome had increased levels of proatherogenic adipocytokines, particularly leptin, leptin-resistance representing the pathogenic link of obesity. The identification as early as possible of the metabolic syndrome patients allows effective monitoring and correction of cardiovascular risk factors, with the opportunity to reduce morbidity and mortality in young ages. In men, proatherogenic cytokines values presented higher values than in women, which prove the role of abdominal obesity in proatherogenic cytokines production. Although women have a higher percentage of adipose tissue, this is not primarily abdominal adipose tissue.

Citing Articles

Relationship between Cytokines and Metabolic Syndrome Components: Role of Pancreatic-Derived Factor, Interleukin-37, and Tumor Necrosis Factor-α in Metabolic Syndrome Patients.

Abdel-Moneim A, Mahmoud R, Allam G, Mahmoud B Indian J Clin Biochem. 2024; 39(1):37-46.

PMID: 38223016 PMC: 10784435. DOI: 10.1007/s12291-022-01079-z.


Association Between Dietary Zinc Intake and Metabolic Syndrome. A Meta-Analysis of Observational Studies.

Ding J, Liu Q, Liu Z, Guo H, Liang J, Zhang Y Front Nutr. 2022; 9:825913.

PMID: 35187040 PMC: 8850691. DOI: 10.3389/fnut.2022.825913.


Diagnostic Power of Circulatory Metabolic Biomarkers as Metabolic Syndrome Risk Predictors in Community-Dwelling Older Adults in Northwest of England (A Feasibility Study).

Hassannejad R, Sharrouf H, Haghighatdoost F, Kirk B, Amirabdollahian F Nutrients. 2021; 13(7).

PMID: 34209146 PMC: 8308366. DOI: 10.3390/nu13072275.


Metabolic syndrome and subchondral bone alterations: The rise of osteoarthritis - A review.

Azzini G, Santos G, Visoni S, Marques Azzini V, Santos R, Huber S J Clin Orthop Trauma. 2020; 11(Suppl 5):S849-S855.

PMID: 32999567 PMC: 7503158. DOI: 10.1016/j.jcot.2020.06.021.


Design and implementation of a cross-sectional nutritional phenotyping study in healthy US adults.

Baldiviez L, Keim N, Laugero K, Hwang D, Huang L, Woodhouse L BMC Nutr. 2020; 3:79.

PMID: 32153856 PMC: 7050916. DOI: 10.1186/s40795-017-0197-4.